The combination of cyclophosphamide and oxaliplatin in NSCLC patients significantly increased nuclear HMGB1 staining in tumor nodules; Also, the oxaliplatin cyclophosphamide combination was able to control tumor growth (95). The gene discussed is HMGB1; the disease is neoplasm.